Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Roche | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Roche

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche

FY Revenues: $34.5 billion (+17%)*

FY Earnings: $7.3 billion (+34%)*

Comments: Pharmaceutical sales were up 21% to $27.3 billion driven primarily by key oncology products: MabThera/Rituxan, Herceptin, Avastin, and Xeloda; the flu medicine Tamiflu, Genentech’s ophthalmology drug Lucentis, and the osteoporosis medicine Bonviva/Boniva. The company received marketing approvals for Avastin in lung cancer, Herceptin in early-stage breast cancer and MabThera/Rituxan in rheumatoid arthritis. R&D spending was $5.4 billion for the year, up 16%.

* includes revenues from Genentech and Chugai subsidiaries

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters